# US 2024/0197707 A1 · Compositions and their Use for the Treatment of A1-Antitrypsin Deficiency

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2024/0197707 A1
- Document ID: US20240197707A1
- Status: Published application
- Kind: A1
- Application number: 18/540,695
- Filed: 2023-12-14
- Published: 2024-06-20
- Earliest claimed: 2021-06-15
- Assignees: Centessa Pharmaceuticals (UK) Limited
- Applicants: Centessa Pharmaceuticals (UK) Limited
- Inventors: Nigel RAMSDEN; David John FOX; James Andrew HUNTINGTON
- Web page: https://patentgrep.com/patent/US20240197707A1

## CPC

- A61K 31/445: Non condensed piperidines, e.g. piperocaine
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The invention relates to pharmaceutical compositions comprising (S)-1-(2-(trifluoromethyl)phenyl)sulfonyl)piperidine-3-carboxylic acid and their medical use, for example for use in the treatment of α1-antitrypsin deficiency (AATD).

## Claims

### Claim 1

A pharmaceutical composition comprising the compound (S)-1-((2-(trifluoromethyl)phenyl)sulfonyl)piperidine-3-carboxylic acid
for use in treating a disease or disorder characterised by low plasma levels of α1-antitrypsin (A1AT) in a human subject, wherein the composition is administered to the human subject at a daily dose of about 1-6 mg/kg.

### Claim 2 (depends on 1)

The pharmaceutical composition for use according to claim 1, wherein the composition is administered to the human subject at a daily dose of about 2-5 mg/kg, for example about 2 mg/kg, about 3 mg/kg, about 4 mg/kg or about 5 mg/kg.

### Claim 3 (depends on 1, 2)

The pharmaceutical composition for use according to either of claim 1 or claim 2, further comprising a pharmaceutically or therapeutically acceptable excipient or carrier.

### Claim 4

The pharmaceutical composition for use according any of the preceding claims, in which the composition is administered in oral form or intravenously.

### Claim 5 (depends on 1)

Use of a compound as defined in claim 1 in the manufacture of a medicament for the treatment of a disease or disorder characterised by low plasma levels of A1AT in a human subject, wherein the medicament is administered to the human subject at a daily dose of about 1-6 mg/kg.

### Claim 6 (depends on 1, 2, 3, 4)

A method of treating a disease or disorder characterised by low plasma levels of A1AT in a human subject, comprising the step of administering a pharmaceutical composition as defined in any of claims 1-4 at a daily dose of about 1-6 mg/kg.

### Claim 7 (depends on 1, 2, 3, 4, 5, 6)

The pharmaceutical composition for use according any of claims 1 to 4, the compound for use according to claim 5, or the method according to claim 6, in which the disease or disorder is α1-antitrypsin deficiency (AATD).
